neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1340-1349

  Andrulis, Irene L ^a   Bull, Shelley B ^a   Blackstein, Martin E ^a   Sutherland, Donald ^a   Mak, Carmen ^a   Sidlofsky, Saul ^a   Pritzker, Kenneth P H ^a   Hartwick, R Warren ^a   Hanna, Wedad ^a   Lickley, Lavina ^a   Wilkinson, Robert ^a   Qizilbash, A ^a   Ambus, Ulo ^a   Lipa, Michael ^a   Weizel, Harold ^a   Katz, Allan ^a   Baida, Michael ^a   Mariz, Segundo ^a   Stoik, Gary ^a   Dacamara, Pamela ^a   Strongitharm, Donna ^a   Geddie, William ^a   McCready, David ^a   more..

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0031954313     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1340     Document Type: Article

References (43)

1. Fisher B, Bauer M, Wickerham DL, et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52:1551-1557, 1983
2. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989.
3. McGuire WL, Clark GM, Dressler LG, et al: Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monogr 1:19-23, 1986
4. Henson DE, Ries L, Freedman LS, et al: Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer: The basis for a prognostic index. Cancer 68:2142-2149, 1991
5. Osborne CK: Receptors, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases (ed 2). Philadelphia, PA, Lippincott, 1991, pp 301-325
6. Fisher B, Redmond C, Dimitrov NV, et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in treatment of patients with node-negative breast cancer who have ER-negative tumors. N Engl J Med 320:473-478, 1989
7. Fisher B, Constantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 320:479-484, 1989
8. Mansour EG, Gray R, Shatila AH, et al: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med 320:485-490, 1989
9. The Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491-496, 1989
10. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1992
11. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976, 1985
12. Coussens L, Yang-Feng TL, Chen Y-CLE, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares choromosomal location with neu oncogene. Science 230:1132-1139, 1985
13. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER/neu oncogene. Science 235:177-182, 1987
14. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
15. Berger MS, Locher GW, Saurer S, et al: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1988
16. Paterson MC, Dietrich KD, Danyluk J, et al: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51:556-567, 1991
17. van de Vijver MJ, Peterse JL, Mooi WJ, et al: Neu-protein overexpression in breast cancer. N Engl J Med 319:1239-1245, 1988
18. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
19. Seshadri R, Firgaira FA, Horsafall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11:1936-1942, 1993
20. Ro JS, el-Naggar A, Ro JY, et al: c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49:6941-6944, 1989
21. Tandon AK, Clark GM, Chamness GC, et al: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1989
22. Wright C, Angus B, Nicholson S, et al: Expression of c-erbB-2 onco-protein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
23. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 7:1049-1056, 1992
24. Paik S, Hazan R, Fisher E, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein over-expression in primary breast cancer. J Clin Oncol 1:103-112, 1990
25. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of over-expression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
26. Press MF, Pike MC, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
27. Elston CW, Wllis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
28. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-377, 1957
29. Fisher ER, Redmond C, Fisher B: Histologic grading of breast cancer. Pathol Annu 15:239-251, 1980
30. American Joint Committee on Cancer: Manual for Staging of Cancer (ed 4). Chicago, IL, American Cancer Society 1992, pp 149-152
31. Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
32. Heng, HH, Shi X-M, Scherer SW, et al: Refined localization of the human asparagine synthetase gene (ASNS) to chromosome 7q21.3 and characterization of the somatic hybrid cell line 4AF/106/KO15. Cytogenet Cell Genet 66:135-138, 1994
33. n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 91:12155-12158, 1994
34. Lin JC, Scherer SW, Tougas L, et al: Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET. Oncogene 13:2001-2008, 1996
35. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1:121-129, 1982
36. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B 34:187-220, 1972
37. LeBlanc M, Crowley T: Relative risk trees for censored survival data. Biometrics 48:411-425, 1992
38. Grambsch P, Therneau T: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
39. Clemente CG, Boracchi P, Andreola S, et al: Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 69:1396-1403, 1992
40. Gasparini G, Meli S, Panizzoni GA, et al: Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer. Breast Cancer Res Treat 20:195-204, 1991
41. Gilchrist KW, Gould VE, Hirsch S, et al: Interobserver variation in the identification of breast carcinoma in intramammary lymphatics. Hum Pathol 13:170-172, 1982
42. Lee AKC, DeLellis RA, Silverman ML, et al: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 8:1457-1465, 1990
43. Hanna W, Kahn HJ, Andrulis IL, et al: Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases. Mod Pathol 3:455-461, 1990